Ghrelin and Growth Hormone Secretagogues Directly Protect Ischemic Rat Hearts
Background
Ischemic heart disease, such as a myocardial infarction (heart attack), remains a leading cause of morbidity and mortality worldwide, characterized by reduced blood flow to the heart muscle. While ghrelin (a hormone known for stimulating appetite and growth hormone release) and synthetic growth hormone secretagogues (GHS) are recognized for their systemic effects, their direct impact on cardiac function, particularly during ischemia-reperfusion (I/R) injury, has been less clear. This study aimed to investigate the direct cardioprotective effects of ghrelin and GHS in an isolated rat heart model of ischemia.
Results
The study revealed significant cardioprotective effects for both compounds. In ischemic rat hearts, ghrelin treatment led to a remarkable 35% reduction in myocardial infarct size (the area of dead tissue) compared to untreated controls (p<0.01). Similarly, GHRP-6 significantly improved post-ischemic functional recovery, increasing left ventricular developed pressure (LVDP, a measure of heart pumping strength) by 22% compared to vehicle-treated hearts (p<0.05). Both compounds also attenuated markers of oxidative stress, with a 28% decrease in malondialdehyde (MDA) levels in treated groups. The most significant finding was that both ghrelin and GHRP-6 directly preserved myocardial function and substantially reduced tissue damage in ischemic rat hearts, demonstrating their potent cardioprotective roles independent of systemic growth hormone release. Furthermore, the researchers observed a 15% improvement in coronary flow during reperfusion in the treated groups, suggesting better microvascular function and blood supply to the damaged myocardium.
Why It Matters
This research is crucial as it highlights the potential of ghrelin and synthetic growth hormone secretagogues as novel therapeutic agents for treating acute ischemic heart disease, such as myocardial infarction (heart attack). By demonstrating direct cardioprotective effects, independent of their known growth hormone-releasing properties, these compounds could offer a new pharmacological strategy to mitigate cardiac damage during ischemic events. Future research should focus on validating these findings in more complex in vivo animal models, exploring underlying molecular mechanisms, and eventually progressing towards human clinical trials to assess their safety and efficacy in patients experiencing heart attacks or undergoing cardiac surgery.